
 --17. A therapeutic composition for inhibition of tumor associated angiogenesis or for treatment of tumor associated angiogenesis, comprising an antibody selected from the group consisting of an antibody which specifically binds proliferating human endothelial cells, a monoclonal antibody which specifically binds proliferating human endothelial cells, an antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), an antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), a monoclonal antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), a monoclonal antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), and an antibody-conjugate comprising an antibody and a conjugate material, said antibody of said antibody-conjugate being selected from the group consisting of an antibody which specifically binds proliferating human endothelial cells, a monoclonal antibody which specifically binds proliferating human endothelial cells, an antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), an antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), a monoclonal antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), and a monoclonal antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), and said conjugate material being selected from the group consisting of a toxin material, a label, a cytotoxic material, ricin A chain, diphtheria toxin, Pseudomonas exotoxin A, idarubicin, a radioisotope label, and technetium-99m;

together with a pharmaceutically acceptable carrier.--

--18. A method for inhibition of angiogenesis in a patient, said angiogenesis being associated with the growth of solid tumors, the method comprising administering to the patient an inhibition-effective amount of an antibody selected from the group consisting of an antibody which specifically binds proliferating human endothelial cells, a monoclonal antibody which specifically binds proliferating human endothelial cells, an antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), an antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), a monoclonal antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), a monoclonal antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), and an antibody-conjugate comprising an antibody and a conjugate material, said antibody of said antibody-conjugate being selected from the group consisting of an antibody which specifically binds proliferating human endothelial cells, a monoclonal antibody which specifically binds proliferating human endothelial cells, an antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), an antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), a monoclonal antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), and a monoclonal antibody which specifically binds proliferating human umbilical artery

endothelial cells (HUAEC), and said conjugate material being selected from the group consisting of a toxin material, a label, a cytotoxic material, ricin A chain, diphtheria toxin, Pseudomonas exotoxin A, idarubicin, a radioisotope label, and technetium-99m.--

 --19. A method for treatment of tumor associated angiogenesis in a patient, which comprises administration to said patient of a therapeutic-effective amount of an antibody selected from the group consisting of an antibody which specifically binds proliferating human endothelial cells, a monoclonal antibody which specifically binds proliferating human endothelial cells, an antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), an antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), a monoclonal antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), a monoclonal antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), and an antibody-conjugate comprising an antibody and a conjugate material, said antibody of said antibody-conjugate being selected from the group consisting of an antibody which specifically binds proliferating human endothelial cells, a monoclonal antibody which specifically binds proliferating human endothelial cells, an antibody which specifically binds proliferating human umbilical vein endothelial cells (HUVEC), an antibody which specifically binds proliferating human umbilical artery endothelial cells (HUAEC), a